Thus, our study suggests that SMARCA4-deficient NSCLC patients, a significant subgroup of this aggressive disease, may also benefit from this treatment strategy using CDK4/6 inhibitors. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.